Key result
Anatomically guided Et-VOM is linked to ~41% lower recurrence vs EP guidance in repeat perAF ablations.
Why the study?
The optimal ablation strategy after a failed procedure for persistent atrial fibrillation is unknown.
Does an anatomically guided strategy with adjunctive ethanol infusion into the vein of Marshall reduce arrhythmia recurrence compared to an electrophysiology-guided strategy in patients undergoing a second ablation for persistent atrial fibrillation?
Cohort (n=198)
Does an anatomically guided strategy with adjunctive ethanol infusion into the vein of Marshall reduce arrhythmia recurrence compared to an electrophysiology-guided strategy in patients undergoing a second ablation for persistent atrial fibrillation?
Absolute Event Rate: 22% vs 37%
p-value: p=.01
An anatomically guided ablation strategy with adjunctive ethanol infusion into the vein of Marshall significantly reduces arrhythmia recurrence at 1 year compared to an electrophysiology-guided strategy in patients undergoing repeat ablation for persistent atrial fibrillation.
Anatomically guided Et-VOM may lower recurrence in repeat perAF ablation; hypothesis-generating and requires RCT confirmation.
INTRODUCTION: The optimal strategy after a failed ablation for persistent atrial fibrillation (perAF) is unknown. This study evaluated the value of an anatomically guided strategy using a systematic set of linear lesions with adjunctive ethanol infusion into the vein of Marshall (Et-VOM) in patients referred for second perAF ablation procedures. METHODS AND RESULTS: Patients with perAF who underwent a second procedure were grouped according to the two strategies. The first strategy was an anatomically guided approach using systematic linear ablation with adjunctive Et-VOM, with bidirectional blocks at the posterior mitral isthmus (MI), roof, and cavotricuspid isthmus (CTI) as the procedural endpoint (Group I). The second one was an electrophysiology-guided strategy, with atrial tachyarrhythmia termination as the procedural endpoint (Group II). Arrhythmia behavior during the procedure guided the ablation strategy. Groups I and II consisted of 96 patients (65 ± 9 years; 71 men) and 102 patients (63 ± 10 years; 83 men), respectively. Baseline characteristics were comparable. In Group I, Et-VOM was successfully performed in 91/96 (95%), and procedural endpoint (bidirectional block across all three anatomical lines) was achieved in 89/96 (93%). In Group II, procedural endpoint (atrial tachyarrhythmia termination) was achieved in 80/102 (78%). One-year follow-up demonstrated Group I (21/96 [22%]) experienced less recurrence compared to Group II (38/102 [37%], Log-rank p = .01). This was driven by lower AT recurrence in Group I (Group I: 10/96 [10%] vs. Group II: 29/102 [28%]; p = .002). CONCLUSION: Anatomically guided strategy with adjunctive Et-VOM is superior to an electrophysiology-guided strategy for second procedures in patients with perAF at 1-year follow-up.
No takes yet. Share an insight, caveat, or question.
Nakashima et al. (2022) conducted a cohort in Persistent atrial fibrillation (perAF) (n=198). Anatomically guided strategy with adjunctive ethanol infusion into the vein of Marshall (Et-VOM) vs. Electrophysiology-guided strategy was evaluated on Recurrence at 1-year follow-up (p=.01). An anatomically guided strategy with adjunctive Et-VOM reduced recurrence compared to an electrophysiology-guided strategy for second perAF ablations at 1 year (22% vs 37%, p=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: